UBS AG has revised its price target for Carl Zeiss Meditec, lowering it to 65 euros while maintaining a "Neutral" rating on the shares.
The analyst expressed caution in investing in the medical technology company due to an unattractive balance between opportunities and risks, especially after a challenging year for the firm.
Carl Zeiss Meditec shares are currently priced at 62.65 euros, reflecting a modest increase of 0.72%. Ongoing concerns about the company's performance and market positioning suggest that investors should proceed with caution.